PELP1 and prostate carcinoma: Ravindranathan et al. used peptidomimetics to target the conserved α-helix in the LXXLL motif to inhibit PELP1 binding to the AF-2 region of AR to serve as a prostate cancer therapeutic (Fig. 5, A and B) (113).